Weight & metabolism
Semaglutide
Wegovy, Ozempic
Semaglutide is a GLP-1 receptor agonist approved by the FDA for chronic weight management (Wegovy) and type 2 diabetes (Ozempic). It is one of the most extensively studied peptide medicines.
Key facts
- Commonly discussed for: weight management and type 2 diabetes.
- Evidence (A): The STEP 1 trial alone randomized 1,961 adults and found 14.9% average weight loss at 68 weeks versus 2.4% with placebo, and it is supported by a broad phase 3 program.
- FDA status: FDA-approved. FDA approved Wegovy for chronic weight management in June 2021, and FDA reports the semaglutide shortage is resolved, ending the period when broad compounding of copies was tolerated.
- Legitimate access: Rx brand.
- Last reviewed: October 1, 2026.
Read the deep dives
Thinking about Semaglutide?
Add it to your stack, then bring the list to a licensed provider. They can tell you whether it fits your health picture and what the legitimate options are. Peptiblox never sells peptides or links to sellers. Check the legal status tracker for the latest FDA changes.
Open my stack →